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A Commentary on
p31-43 Gliadin Peptide Forms Oligomers and Induces NLRP3 Inflammasome/Caspase 1-
Dependent Mucosal Damage in Small Intestine
by Gómez Castro, M. F., Miculán, E., Herrera, M. G., Ruera, C., Perez, F., Prieto, E. D., et al. (2019).
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In our recent publication p31-43 Gliadin Peptide Forms Oligomers and Induces NLRP3
Inflammasome/Caspase 1- Dependent Mucosal Damage in Small Intestine” (1) we showed by
a combination of experimental and simulation techniques that the peptide p31-43 Gliadin has
an intrinsic propensity to form oligomers, which trigger the NLRP3 inflammasome, resulting
in intestinal inflammation and pathology. In particular, molecular simulations performed with
the SIRAH force field (2), showed that isolated p31-43 peptides exhibit a broad conformational
dynamic with some PPII component, mostly related to the presence of Pro36 and Pro42. Simulation
of multiple replicas showed a spontaneous tendency to aggregation with a concomitant increase in
the PPII content for Pro38 and Pro 39.
After our paper came out, an independent group published the NMR structure of p31-43 and
its P36A and F37A mutants (3). This work presented apparently contrasting results based on NMR
spectroscopy suggesting p31-43 Gliadin is mainly monomeric, but not discarding the presence of
possible aggregated structures. As the peptide structures were deposited in the Protein Data Bank,
we reanalyzed our molecular dynamics trajectory conducting a structural comparison between the
conformations sampled in our simulations and those based on NMR. As it can be observed from
Figure 1A, the matching observed between monomer simulations and experimental structures
is outstanding. Moreover, the structural superposition between individual peptides within the
aggregate and the experimental structures is also remarkable (Figure 1B). This provides support
to the idea that “the monomers are in fast exchange with self-assembled structures” and that “the
3D models represent the secondary elements adopted also in the oligomeric forms” (3). Indeed,
selected conformations from the simulations are indistinguishable from those coming from the
experimental determination (Figure 1C).
Besides highlighting the capacity of our simulation method to characterize the conformational
behavior of peptides (Figure 1), the remarkable agreement between simulations and experiments
in the oligomeric case provides strong support to the hypothesis that the p31-43 Gliadin peptide
suffers very minor conformational changes when passing from monomeric to oligomeric states.
Barrera et al. p31-43 Oligomer/Monomer Are Structurally Indistinguishable
FIGURE 1 | Structural superposition of the best matching solution between NMR derived conformations and simulation of isolated peptides (A), and peptides within
the 50-mer aggregate (B). On (C), the final structures obtained by molecular dynamics of each peptide forming the oligomer (Y-axis) are compared against all the
conformers reported in the NMR family of structures (X-axis). The degree of structural similarity is reported as the root mean square deviation (RMSD) between the
C-alpha carbons of simulated and NMR derived conformers. Small RMSD values (red-yellow) identify high structural similarity. Simulations of P36A and F37A showed
the same degree of structural similarity (not shown).
This further strengthens the idea that aggregates might work
as reservoirs that protect p31-43 from degradation. Though
p31-43 monomers are quite resistant to degradation, the self-
assembly process extends the persistence of large aggregates
with higher toxic potency, particularly when disruption of the
normal physiology of internal vesicles (1) and release of danger
signals are considered as driving events for inflammation and cell
damage (4).
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